← board
OSTX
distress 7/10 · high distress / dilution risk$1.540%today-38% from 52w high
Lead: pulmonary metastatic osteosarcoma
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
+40%
Price & events
+4.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
+2.8%
1W
-15.2%
1M
+6.4%
3M
+4.9%
6M
-15.7%
1Y
—
2Y
—
5Y
-38.5%
All
Overview
- Market Cap
- $68.71M
- Volume
- 22.27K
- 52 Week Range
- $1.16 – $2.50
- Total Shares
- 44.54M
- Float Shares
- 36.21M
- Short %
- 5.46%
- % Held by Insiders
- 22.14%
- % Held by Institutions
- 6.46%
- RVOL
- 0.03x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 11
- early in the fourth quarter of 2026Guided 70%readoutPhase 2OST-HER2 · 3-year overall survival data to complete CMA submissionSEC 8-K
- fourth quarter of 2026Guided 70%chmp opinionCHMP (EU)OST-HER2 · Potential Conditional Marketing Authorisation decisionSEC 8-K
- Q3 2026Guided 70%trial initiationsecondaryPhase 3OST-HER2 · Initiate confirmatory Phase 3 trial in AustraliaSEC 8-K
- April - September 2026Guided 70%PDUFAPDUFAOST-HER2 · FDA Accelerated Approval decision for OST-HER2SEC 8-K
- 2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
- middle of the second quarter of 2026readoutPhase 2OST-HER2 · 2.5-year overall survival data updateSEC 8-K
- 2026-04-30fda agreementOST-HER2 · Alignment with EMA and ATGA on 3-year OS as primary endpoint and seroconversion as surrogateSEC 8-K
- Q4/25 – Q1/26regulatory submissionFiled (NDA/BLA)OST-HER2 · Regulatory pathway for OST-HER2 in canine osteosarcomaSEC 8-K
- in 2025regulatory submissionFiled (NDA/BLA)OST-HER2 · Submit BLA to FDA for OST-HER2SEC 8-K
- 2025-08-25withdrawalTerminated ELOC with Square GateSEC 8-K
- 2025-04-09partnershipADXS-503, ADXS-504, OST-HER2 · Acquired Lm-based immune-oncology programs and IP assets from Ayala Pharmaceuticals, including ADXS-503 (NSCLC), ADXS-504 (prostate cancer), and OST-HER2.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+478% upside) · 5 analysts
- 2026-07-09Roth CapitalBuy
- 2026-05-19Lake StreetBuy
- 2026-04-30D. Boral CapitalBuy
- 2026-04-08D. Boral CapitalBuy
- 2026-03-27D. Boral CapitalBuy
- 2026-03-09D. Boral CapitalBuy
Competitors — pulmonary metastatic osteosarcoma
- none identified
Recent news
- 2026-07-18OS Therapies (OSTX) price target increased by 16.67% to 14.28 - MSN
- 2026-07-17OS THERAPIES INC (OSTX) Stock Chart - ChartMill
- 2026-07-16OS Therapies (NYSE American: OSTX) sells $1.6M in Rule 506(b) private securities deal - Stock Titan
- 2026-07-16OS Therapies Incorporated (NYSE: OSTX) Stock Price, News & Analysis - Kalkine
- 2026-07-16OS Therapies (OSTX) Experiences Steep Decline as Support Levels Come into Focus - Weak Sell Signals - dars.gov.et
- 2026-07-11OS Therapies (OSTX) Faces Continued Pressure as Shares Test Key Support - Advance Decline Line - dars.gov.et
- 2026-07-09OSTX Initiated Coverage By Roth Capital -- Price Target Set at $7.00 - GuruFocus
- 2026-07-09Why is OS Therapies stock surging today? By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.